Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

BackgroundEnhanced activity of histone deacetylases (HDAC) is associated with more aggressive tumour behaviour and tumour progression in various solid tumours. The over-expression of these proteins and their known functions in malignant neoplasms has led to the development of HDAC inhibitors (HDI) as new anti-neoplastic drugs. However, little is known about HDAC expression in renal cell cancer.MethodsWe investigated the expression of HDAC 1, 2 and 3 in 106 renal cell carcinomas and corresponding normal renal tissue by immunohistochemistry on tissue micro arrays and correlated expression data with clinico-pathological parameters including patient survival.ResultsAlmost 60% of renal cell carcinomas expressed the HDAC isoforms 1 and 2. In contrast, HDAC 3 was only detected in 13% of all renal tumours, with particular low expression rates in the clear cell subtype. HDAC 3 was significantly higher expressed in pT1/2 tumours in comparison to pT3/4 tumours. Expression of class I HDAC isoforms correlated with each other and with the proliferative activity of the tumours. We found no prognostic value of the expression of any of the HDAC isoforms in this tumour entity.ConclusionClass I HDAC isoforms 1 and 2 are highly expressed in renal cell cancer, while HDAC 3 shows low, histology dependent expression rates. These unexpected differences in the expression patterns suggests alternative regulatory mechanisms of class I HDACs in renal cell cancer and should be taken into account when trials with isoform selective HDI are being planned. Whether HDAC expression in renal cancers is predictive of responsiveness for HDI will have to be tested in further studies.

• Publication year

  2008

• Venue

  BMC Cancer

• Publication date

  2008-12-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/1471-2407-8-381PMID 19099586PMCID 2631013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis.

  2008cited by this paper
• Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

  2008cited by this paper
• Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

  2008cited by this paper
• Cancer Statistics, 2008

  2008cited by this paper
• Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

  2007cited by this paper
• Expression of HDAC1 and CBP/p300 in human colorectal carcinomas

  2007cited by this paper
• Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial

  2007cited by this paper
• Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma

  2007cited by this paper
• Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin.

  2007cited by this paper
• Epigenetic therapy of cancer: past, present and future

  2006cited by this paper
• Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

  2006cited by this paper
• Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors

  2006cited by this paper
• Histone deacetylase inhibitors: multifunctional anticancer agents.

  2006cited by this paper
• Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression

  2005cited by this paper
• Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.

  2005cited by this paper
• Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study

  2005cited by this paper
• Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis

  2005cited by this paper
• Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies

  2005cited by this paper
• HDAC inhibitors: Double edge sword for TRAIL cancer therapy?

  2005cited by this paper
• Clinical development of histone deacetylase inhibitors as anticancer agents.

  2005cited by this paper
• Modulation of radiation response by histone deacetylase inhibition.

  2005cited by this paper
• Increased expression of histone deacetylase 2 is found in human gastric cancer

  2005cited by this paper
• Loss of Gelsolin expression in human ovarian carcinomas.

  2005cited by this paper
• World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs

  2005cited by this paper
• Epigenetic changes in prostate cancer: implication for diagnosis and treatment.

  2005cited by this paper
• Upregulation and Nuclear Recruitment of HDAC1 in Hormone Refractory Prostate Cancer

  2004cited by this paper
• Histone H4 acetylation and histone deacetylase 1 expression in esophageal squamous cell carcinoma.

  2003cited by this paper
• Anti‐tumor mechanisms of valproate: A novel role for an old drug

  2002cited by this paper
• The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.

  2001cited by this paper
• Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.

  2001cited by this paper
• Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer.

  2001cited by this paper
• Potentiation by specific short-chain fatty acids of differentiation and apoptosis in human colonic carcinoma cell lines.

  1994cited by this paper
• Cancer statistics

  1989cited by this paper

• PJA2 Suppresses Colorectal Cancer Progression by Controlling HDAC2 Degradation and Stability

  2025cites this paper
• Pan-cancer analysis reveals netrin-1 receptors as potential tumor biomarkers and immune-related therapeutic targets

  2025cites this paper
• Novel quinazoline-triazole-based N-hydroxybenzamides/N-hydroxypropenamides as HDAC inhibitors: design, synthesis, biological evaluation, and docking studies

  2025cites this paper
• Comprehensive Characterization of HATs and HDACs in Human Cancers Reveals Their Role in Immune Checkpoint Blockade.

  2024cites this paper
• Autophagy in cancer immunotherapy: Perspective on immune evasion and cell death interactions.

  2024cites this paper
• Recent advances in EZH2-based dual inhibitors in the treatment of cancers.

  2023cites this paper
• Identification of structural fingerprints among natural inhibitors of HDAC1 to accelerate nature-inspired drug discovery in cancer epigenetics

  2023cites this paper
• Protein acetylation and related potential therapeutic strategies in kidney disease.

  2023cites this paper
• Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and in vitro and in vivo biological activity evaluations

  2023cites this paper
• Identification of Novel 4-Oxo-4H-chromen-Hydroxamic Acid Derivative Targeting Selected HDAC Isoforms

  2023cites this paper
• Targeting histone deacetylases for cancer therapy: Trends and challenges

  2023cites this paper
• Curriculum vitae of HDAC6 in solid tumors.

  2023cites this paper
• Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors

  2023cites this paper
• Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications

  2023cites this paper
• Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer

  2022cites this paper
• Brusatol inhibits the growth of renal cell carcinoma by regulating the PTEN/PI3K/AKT pathway.

  2022cites this paper
• Oral histone deacetylase inhibitor HBI-8000 (tucidinostat) in Japanese patients with relapsed or refractory non-Hodgkin’s lymphoma: phase I safety and efficacy

  2022cites this paper
• Decoding molecular recognition of inhibitors targeting HDAC2 via molecular dynamics simulations and configurational entropy estimation

  2022cites this paper
• Treatment of Refractory Metastatic Renal Cell Carcinoma

  2022cites this paper
• Repression of the PRELP gene is relieved by histone deacetylase inhibitors through acetylation of histone H2B lysine 5 in bladder cancer

  2022cites this paper
• Research progress on the antitumor effects of astragaloside IV.

  2022cites this paper
• Insights into Regulators of p53 Acetylation

  2022cites this paper
• Clinical Significance of Histone Deacetylase (HDAC)-1, -2, -4 and -6 Expression in Salivary Gland Tumors

  2021cites this paper
• Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex

  2021cites this paper
• Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia

  2021influential citation
• Expression of HDACs 1, 3 and 8 Is Upregulated in the Presence of Infiltrating Lymphocytes in Uveal Melanoma

  2021cites this paper
• Comprehensive analysis of a new prognosis signature based on histone deacetylases in clear cell renal cell carcinoma

  2021cites this paper
• Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity

  2021cites this paper
• A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation.

  2021cites this paper
• MicroRNAs overexpressed in Crohn’s disease and their interactions with mechanisms of epigenetic regulation explain novel aspects of Crohn’s disease pathogenesis

  2021cites this paper
• Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives

  2021cites this paper
• The roles of histone deacetylases in kidney development and disease

  2021cites this paper
• Curcumin affects the prognosis of renal cell carcinoma through a negative feedback loop of H19/miR-675/HDAC/CTCF

  2021cites this paper
• Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma

  2021cites this paper
• Roles of HDAC2, eIF5, and eIF6 in Lung Cancer Tumorigenesis

  2021cites this paper
• Metabolic regulation in urological tumors: Interplay with epigenetics and epitranscriptomics

  2021cites this paper
• Histone deacetylase-2: A potential regulator and therapeutic target in liver disease (Review)

  2021cites this paper
• A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles.

  2021cites this paper
• Construction of a Prognostic Model for Hepatocellular Carcinoma Based on Immunoautophagy-Related Genes and Tumor Microenvironment

  2021cites this paper
• Effect of Trichostatin A on Histone Deacetylases 1, 2 and 3, p21Cip1/Waf1/Sdi1, p27Kip1, and p57Kip2 Gene Expression in Breast Cancer SK-BR-3 Cell Line

  2020cites this paper
• The design of a novel near-infrared fluorescent HDAC inhibitor and image of tumor cells.

  2020cites this paper
• Design, Synthesis, and Cytotoxic Evaluation of Novel Lupane Triterpenoid Derived Hydroxamates

  2020cites this paper
• Upregulated histone deacetylase 2 gene correlates with the progression of oral squamous cell carcinoma

  2020cites this paper
• Tambulin Targets Histone Deacetylase 1 Inhibiting Cell Growth and Inducing Apoptosis in Human Lung Squamous Cell Carcinoma

  2020cites this paper
• Investigation of the Effect of Zebularine in Comparison to and in Combination with Trichostatin A on p21Cip1/Waf1/Sdi1, p27Kip1, p57Kip2, DNA Methyltransferases and Histone Deacetylases in Colon Cancer LS 180 Cell Line

  2020cites this paper
• Roles of Histone Deacetylases and Inhibitors in Anticancer Therapy

  2020cites this paper
• Synergistic Anti-cancer Effect of Inhibition of Histone Deacetylase and Blockade of the Glycolytic Pathway

  2020cites this paper
• In silico Design of Novel Histone Deacetylase 4 Inhibitors: Design Guidelines for Improved Binding Affinity

  2019cites this paper
• The p300/YY1/miR-500a-5p/HDAC2 signalling axis regulates cell proliferation in human colorectal cancer

  2019cites this paper
• The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma

  2019cites this paper
• Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma.

  2019cites this paper
• Autophagy: A novel mechanism of chemoresistance in cancers.

  2019cites this paper
• HDAC2 Regulates Glial Cell Activation in Ischemic Mouse Retina

  2019cites this paper
• Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma

  2019cites this paper
• Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers

  2019cites this paper
• HDAC1-induced epigenetic silencing of ASPP2 promotes cell motility, tumour growth and drug resistance in renal cell carcinoma.

  2018cites this paper
• Therapeutic effects of histone deacetylase inhibitors on kidney disease

  2018cites this paper
• Design of Potent Panobinostat Histone Deacetylase Inhibitor Derivatives: Molecular Considerations for Enhanced Isozyme Selectivity between HDAC2 and HDAC8

  2018cites this paper
• Design, synthesis and biological evaluation of novel 2-aminobenzamides containing dithiocarbamate moiety as histone deacetylase inhibitors and potent antitumor agents.

  2018cites this paper
• The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells

  2018cites this paper
• Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.

  2017cites this paper
• Epigenome Aberrations: Emerging Driving Factors of the Clear Cell Renal Cell Carcinoma

  2017cites this paper
• HDAC 9 associates with distant metastasis and predicts poor prognosis in clear cell renal cell cancer

  2017cites this paper
• Expression patterns of class I histone deacetylases in osteosarcoma: a novel prognostic marker with potential therapeutic implications

  2017cites this paper
• Histone Deacetylase Inhibition Induces Apoptosis and Cell Cycle Dysregulation in Human and Murine Cancer Cell Lines

  2017cites this paper
• Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5

  2017cites this paper
• Understanding HDAC8-Catalyzed Deacetylation:From New Substrates to Diseases

  2017cites this paper
• Animacroxam, a Novel Dual-Mode Compound Targeting Histone Deacetylases and Cytoskeletal Integrity of Testicular Germ Cell Cancer Cells

  2017cites this paper
• Marked for death: targeting epigenetic changes in cancer

  2017cites this paper
• HDAC2 regulates cell proliferation, cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC9706 cells.

  2017cites this paper
• Therapeutic effects of histone deacetylase inhibitors on kidney disease

  2017cites this paper
• Lysine acetylation and cancer: A proteomics perspective.

  2017cites this paper
• Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer

  2017cites this paper
• Epigenetic Regulation of Signalling Pathways in Pancreatic Cancer

  2017influential citation
• Bagging Nearest-Neighbor Prediction independence Test: an efficient method for nonlinear dependence of two continuous variables

  2017cites this paper
• Clinicopathologic Significance of the Expression of SPOCK 1 and HDAC 1 in Urothelial Bladder Cancer ; An Immunohistochemical Study

  2017cites this paper
• Histone deacetylase HDAC1 expression correlates with the progression and prognosis of lung cancer

  2017cites this paper
• The expression of histone deacetylase HDAC1 correlates with the progression and prognosis of gastrointestinal malignancy

  2017cites this paper
• Metal-dependent Deacetylases: Cancer and Epigenetic Regulators.

  2016cites this paper
• Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma

  2016cites this paper
• Expression of microRNA-195 is transactivated by Sp1 but inhibited by histone deacetylase 3 in hepatocellular carcinoma cells.

  2016cites this paper
• HDACs and HDAC Inhibitors in Cancer Development and Therapy.

  2016cites this paper
• Epigenetic therapy in urologic cancers: an update on clinical trials

  2016influential citation
• Epigenomic regulation of oncogenesis by chromatin remodeling

  2016cites this paper
• HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma

  2016cites this paper
• HDAC 2 regulates cell proliferation , cell cycle progression and cell apoptosis in esophageal squamous cell carcinoma EC 9706 cells

  2016cites this paper
• HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy.

  2016cites this paper
• Biomarkers for diet in cancer prevention studies

  2016cites this paper
• Unlocking an HDAC Toolbox: Methods toward Understanding Isozyme-specific Activity.

  2016cites this paper
• The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells

  2015cites this paper
• The Role of Epigenomics in the Study of Cancer Biomarkers and in the Development of Diagnostic Tools.

  2015cites this paper
• c‐Abl induces stabilization of histone deacetylase 1 (HDAC1) in a kinase activity‐dependent manner

  2015cites this paper
• Combination treatment of renal cell carcinoma with belinostat and 5-fluorouracil: a role for oxidative stress induced DNA damage and HSP90 regulated thymidine synthase.

  2015cites this paper
• Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival

  2015cites this paper
• Connexin 43 expression predicts poor progression-free survival in patients with non-muscle invasive urothelial bladder cancer

  2015cites this paper
• An HDAC-Targeted Imaging Probe LBH589-Cy5.5 for Tumor Detection and Therapy Evaluation.

  2015cites this paper
• Epigenetic and Signaling Pathway Regulation in Hair Cell Regeneration

  2015cites this paper
• The Proteomic Profile of Deleted in Breast Cancer 1 (DBC1) Interactions Points to a Multifaceted Regulation of Gene Expression*

  2015cites this paper
• HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population

  2015cites this paper
• Histone deacetylase HDAC1 downregulates transcription of the serotonin transporter (5-HTT) gene in tumor cells.

  2015cites this paper